U.S. markets closed
  • S&P 500

    3,841.47
    -11.60 (-0.30%)
     
  • Dow 30

    30,996.98
    -179.03 (-0.57%)
     
  • Nasdaq

    13,543.06
    +12.15 (+0.09%)
     
  • Russell 2000

    2,168.76
    +27.34 (+1.28%)
     
  • Crude Oil

    51.98
    -1.15 (-2.16%)
     
  • Gold

    1,855.50
    -10.40 (-0.56%)
     
  • Silver

    25.57
    -0.29 (-1.12%)
     
  • EUR/USD

    1.2174
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.0910
    -0.0180 (-1.62%)
     
  • GBP/USD

    1.3685
    -0.0046 (-0.33%)
     
  • USD/JPY

    103.7500
    +0.2450 (+0.24%)
     
  • BTC-USD

    32,285.50
    -373.19 (-1.14%)
     
  • CMC Crypto 200

    651.44
    +41.45 (+6.79%)
     
  • FTSE 100

    6,695.07
    -20.35 (-0.30%)
     
  • Nikkei 225

    28,631.45
    -125.41 (-0.44%)
     

AstraZeneca-Oxford Vaccine at 70% Efficacy

Mark Vickery
·2 min read

Monday, November 23, 2020

Perhaps eventually someone will make a catchy marketing slogan for this time period, but for now I’ll use the term “Vaccine Monday.” For the third Monday in as many weeks, information on a Covid-19 vaccine candidate has been released, with good news once again: the joint effort between Cambridge, England-based AstraZeneca AZN and Oxford University has produced an average 70% efficacy rate in immunizing patients against Covid-19.

This, of course, follows the Pfizer PFE-BioNTech BNTX report that first claimed 90% efficacy, later revised up to 95%. Then, Cambridge, MA-based Moderna MRNA released 94% efficacy. These are all tremendous developments in what will eventually be a post-coronavirus world. For the AstraZeneca-Oxford study, one dosing regimen also demonstrated 90% efficacy. And the one very positive piece of news from this study is that the doses may be refrigerated at normal cooler temperatures. This vaccine is also different from the other candidates, in that it is not an mRNA treatment.

So far, 23K patients have participated in the trial. It is expected to climb to 60K before the trial is completed. AstraZeneca plans to produce 3 million doses next year, provided the remainder of the trial’s checklist is satisfied. Shares of AstraZeneca are down 2% in today’s pre-market, though market indexes overall are in the green at this hour.

It’s a holiday-shortened week of trading, in what is shaping up to be the best month of trading since April for the Dow and the S&P 500. Thanksgiving on Thursday, of course, is a national holiday, and stock exchanges will close at 1pm ET Friday — in what was recently (or still is) referred to as “Black Friday.” Thus, we’ll see jobless claims data a day early this week, on Wednesday.

And, oh yeah — today’s the day to take the turkey out of the freezer!

Questions or comments about this article and/or its author? Click here>>
https://www.zacks.com/bio/mark-vickery

MARKETTINGTEXTSTART Will you retire a millionaire? MARKETTINGTEXTEND


MARKETTINGTEXTSTART One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.” MARKETTINGTEXTEND


MARKETTINGTEXTSTART Click to get it free >> MARKETTINGTEXTEND


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AstraZeneca PLC (AZN) : Free Stock Analysis Report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
Moderna, Inc. (MRNA) : Free Stock Analysis Report
 
BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research
 
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report